News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
1569
Sources here
13
Companies here
24
Search results Stored financial headlines

Active search

1569 matching headlines

Ticker or company: STRAMain company stories
Clear
Latest

finance.yahoo.com Analyst action

AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), one of the world's largest pharmaceutical companies with a major focus on oncology, ended its Phase III eVOLVE-Lung02 trial after an independent committee concluded that volrustomig combined with chemotherapy was unlikely to outperform existing treatment options in improving progression-free or overall survival. The study covered 895 patients with metastatic non-small-cell …

Vistra Is Under $150. Here's Why I Think It Won't Stay That Way.

Vistra's (NYSE: VST) stock has surged in recent years as energy demand has exploded, powered by artificial intelligence (AI) data centers. However, shares of the power generation company have cooled down this year amid concerns about pushback on behind-the-meter deals with hyperscalers, and it's …

VST main company VST main company
Sharemaestro market context Price below Trend Line 52 weeks -29.3% · Next-week setup negative 44.2% VST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

AstraZeneca ditches lung cancer treatment trial

Drug giant AstraZeneca has revealed its latest setback in just over a month after halting a late stage lung cancer treatment trial. The FTSE 100 firm said it found its Volrustomig drug, when combined with chemotherapy, was unlikely to boost survival rates for lung …

AZN main company AZN1N main company AZN main company A1ZN34 main company AZN main company AZN main company
Sharemaestro market context Price below Trend Line 52 weeks +14.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

[A big sign with AstraZeneca logotype outside the entrance.] Wirestock * AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded the drug was unlikely to meet either primary …

AZN main company AZN1N main company AZN main company A1ZN34 main company AZN main company AZN main company
Sharemaestro market context Price below Trend Line 52 weeks +14.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Why Strategy (MSTR) Shares Are Trading Lower Today

Why Strategy (MSTR) Shares Are Trading Lower Today What Happened? Shares of bitcoin development company Strategy (NASDAQ:MSTR) fell 3.5% in the afternoon session after index provider MSCI proposed removing the company from its Global Investable Market Indexes, compounding concerns over recent sales of its …

MSTR main company
Sharemaestro market context Price below Trend Line 52 weeks -74.0% · Next-week setup negative 44.5% MSTR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Small Cap Watch: D3 Energy, Astral Resources, Surefire and Dalaroo advance company programs

Small Cap Watch: D3 Energy, Astral Resources, Surefire and Dalaroo advance company programs Proactive uses images sourced from Shutterstock The S&P/ASX Small Ordinaries (ASX: XSO) finished Friday at 3,517.10 points, down 24.30 points or 0.69% for the session. Over the past five trading days, …

AAR main company
Sharemaestro market context Price below Trend Line 52 weeks -9.1% · Next-week setup negative 36.0% AAR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Vistra (VST) Stock Looks Above Fair Value On Earnings Yet Supported By Demand

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Vistra has delivered a very large 5 year return, yet on current checks the stock now looks closer to fairly valued than clearly cheap, which …

VST main company VST main company
Sharemaestro market context Price below Trend Line 52 weeks -29.3% · Next-week setup negative 44.2% VST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

VST - Vistra Energy ($VST): The Flexible Power Platform Capturing AI Load Growth

Vistra Energy (VST) is positioned as a flexible power platform uniquely capturing AI load growth, despite being largely priced as a volatile merchant generator. The company is strategically converting nuclear assets into long-duration contracted cash flows with hyperscalers like Meta and AWS, while expanding …

VST main company
Sharemaestro market context Price below Trend Line 52 weeks -21.9% · Next-week setup positive 56.7% VST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Strategy (MSTR) Could Be Dropped From Global Indexes In Bitcoin Treasury Review

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. MSCI is reviewing whether to remove Strategy Inc (NasdaqGS:MSTR) and other Bitcoin treasury stocks from its global equity indexes, reopening a consultation that …

MSTR main company
Sharemaestro market context Price below Trend Line 52 weeks -74.0% · Next-week setup negative 44.5% MSTR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

S&CO Inc. Takes Position in Astrazeneca Plc $AZN

S&CO Inc. has acquired a new stake in AstraZeneca Plc, purchasing 37,990 shares valued at approximately $7.1 million during the second quarter. Institutional investors now collectively own 20.35% of AstraZeneca's stock. Analysts maintain a "Moderate Buy" rating for AstraZeneca, with an average price target …

AZN main company
Sharemaestro market context Price below Trend Line 52 weeks -1.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Vistra Corp. (NYSE:VST) Receives Average Rating of "Buy" from Analysts

Vistra Corp. (NYSE:VST) has received an average "Buy" rating from seventeen brokerages, with an average 12-month price target of $228.56. Institutional investors hold a significant 90.88% of the company's stock, and Vistra recently declared a quarterly dividend of $0.23 per share. Despite some insider …

VST main company
Sharemaestro market context Price below Trend Line 52 weeks -21.9% · Next-week setup positive 56.7% VST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kestra Medical Technologies CEO Brian Webster sells $692,214 in stock

Kestra Medical Technologies CEO Brian Webster recently sold $692,214 worth of company stock across three transactions between July 30 and August 3, 2026. These sales were nondiscretionary, executed to cover tax withholding obligations related to restricted stock unit vesting. The company has seen significant …

KMTS main company
Sharemaestro market context Trend signal started 52 weeks +50.8% KMTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kestra Medical CBO Timothy Moran sells $348,310 in shares

Kestra Medical's CBO, Timothy P. Moran, sold $348,310 worth of common shares in late July and early August 2026 to cover tax withholding obligations. Following these transactions, Moran directly owns 66,345 shares. The stock has appreciated significantly since then, despite the company missing Wall …

KMTS main company
Sharemaestro market context Trend signal started 52 weeks +50.8% KMTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kestra Medical Technologies officer Traci Umberger sells $512,791

Traci S. Umberger, General Counsel and Chief Administrative Officer at Kestra Medical Technologies, sold common shares worth $512,791 between July 30 and August 3, 2026. These non-discretionary sales were conducted to cover tax withholding obligations related to restricted stock unit vesting. Following these transactions, …

KMTS main company
Sharemaestro market context Trend signal started 52 weeks +50.8% KMTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Health Savings Account Strategy: How to Turn Your 401(k) Into a Tax-Free Retirement Machine

Quick Read The HSA is the only account offering deductible contributions, tax-free growth, and tax-free medical withdrawals, which is a triple advantage that no 401(k) can match. Fidelity estimates a retiring couple faces roughly $410,000 in healthcare costs over 25 years, the exact bill …

MSTR main company MSTR main company
Sharemaestro market context Price below Trend Line 52 weeks -69.2% · Next-week setup negative 42.5% MSTR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

The Solo 401(k) Strategy That Lets High Earners Dodge $12,000 in Annual Taxes

Quick Read Consultants with side-hustle LLCs can shelter roughly 20% of net self-employment earnings in a Solo 401(k) profit-sharing slot, entirely separate from their workplace plan's limits. On $250,000 of consulting income, that profit-sharing slot adds up to $50,000 in pre-tax contributions, saving roughly …

MSTR main company MSTR main company
Sharemaestro market context Price below Trend Line 52 weeks -69.2% · Next-week setup negative 42.5% MSTR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context